The parental patients of PDX_489 and PDX_545 received anti-EGFR therapy, HNSCC_489 exhibited clinical benefit (−52.12%) and HNSCC_545 had a modest tumor response (−5.08%) and a brief progression-free survival (~1 month). This evidence concerns the gene EGFR and neoplasm.